Ignite Creation Date:
2024-05-06 @ 12:06 AM
Last Modification Date:
2024-10-26 @ 10:45 AM
Study NCT ID:
NCT01492777
Status:
COMPLETED
Last Update Posted:
2013-06-21
First Post:
2011-12-13
Brief Title:
Pharmacogenetics of Acenocoumarol
Sponsor:
University Hospital Geneva
Organization:
University Hospital Geneva
Study Overview
Official Title:
Stabilization of Anticoagulation by Acenocoumarol Role of Genetic Vulnerability and Risk of Drug Interactions
Status:
COMPLETED
Status Verified Date:
2013-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The use of oral anticoagulation is marked by an elevated risk of adverse drug events ADE due to a narrow therapeutic window leading to important medical and economical consequences The risk of ADE is increased partly by drug interactions and recently identified genetic factors influencing the metabolism of coumarins polymorphism of the cytochrome P450 CYP2C9 as well as the target enzyme of the coumarins polymorphism of the vitamin K epoxide reductase complex subunit 1 VKORC1
The objective is to determine the impact of several genotypes on acenocoumarol treatment and on vulnerability to drug-drug interactions
The objective is to determine the impact of several genotypes on acenocoumarol treatment and on vulnerability to drug-drug interactions
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None